Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 230Breast Neoplasms 187Ovarian Neoplasms 113Neoplasms 100Neoplasm Metastasis 59Lung Neoplasms 54Fallopian Tube Neoplasms 47Triple Negative Breast Neoplasms 44Stomach Neoplasms 41Parkinson Disease 4, Autosomal Dominant Lewy Body 41Endometrial Neoplasms 37Carcinoma, Ovarian Epithelial 32Squamous Cell Carcinoma of Head and Neck 28Uterine Cervical Neoplasms 24Esophageal Neoplasms 21Carcinoma 21Colorectal Neoplasms 20Recurrence 19Melanoma 18Esophageal Squamous Cell Carcinoma 18Small Cell Lung Carcinoma 16Pancreatic Neoplasms 16Head and Neck Neoplasms 14Solid Tumors 12Adenocarcinoma 12Advanced Solid Tumors 11Carcinoma, Renal Cell 10Carcinoma, Squamous Cell 9Urinary Bladder Neoplasms 8Solid Tumor 8

Interventions

adavosertib 1Paclitaxel 1Gemcitabine 1Carboplatin 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation × Paclitaxel × Clear all
NCT02272790 2023-10-03

Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

AstraZeneca

Phase 2 Completed
95 enrolled 61 charts
Gynecologic

Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡